Skip to main content
REPLIGEN CORP logo

REPLIGEN CORP — Investor Relations & Filings

Ticker · RGEN ISIN · US7599161095 LEI · 54930006QJ0T5AUO1E71 US Manufacturing
Open in API
Filings indexed 1,029 across all filing types
Latest filing 2020-08-05 Director's Dealing
Country US United States of America
Listing US RGEN

About REPLIGEN CORP

https://www.repligen.com/

Repligen Corporation is a life sciences company that develops and commercializes innovative bioprocessing technologies and systems used in the manufacturing of biologic drugs. The company's portfolio is focused on enhancing efficiency and quality in biopharmaceutical production workflows. Key product areas include filtration, featuring Tangential Flow Filtration (TFF) systems; fluid management, with single-use technologies such as bags, assemblies, and mixers; and process analytics, offering advanced instruments for concentration measurement. Repligen's technologies are integral to the development and cGMP manufacturing of therapies like monoclonal antibodies, vaccines, and cell and gene therapies.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-08-05 English
10-Q
Interim / Quarterly Report Q2 2020
2020-07-31 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company announced its financial results for the second quarter ended June 30, 2020, and that the full press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3372 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase 'announced its financial results' and the presence of a press release exhibit indicate this is an Earnings Release type document. Therefore, the appropriate classification is Earnings Release (ER).
2020-07-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease amendment expanding the leased premises. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a report publication announcement since it contains substantive information about a material agreement. This type of filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-07-10 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the acquisition of Engineered Molding Technologies LLC by Repligen Corporation, including details about the purchase agreement and a press release attached as an exhibit. This indicates the document is announcing a merger/acquisition event. The Form 8-K is not a full merger proxy statement or tender offer filing but an announcement of M&A activity. Therefore, the appropriate classification is 'M&A Activity' (TAR). The document length is 3101 characters, which is typical for an 8-K announcement and not a full detailed report or proxy statement.
2020-06-29 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.